Vindesine as a single agent in the treatment of advanced malignant melanoma
- 1 January 1979
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 2 (4) , 257-260
- https://doi.org/10.1007/bf00257190
Abstract
Summary The antitumour effect of vindesine (desacetyl vinblastine amide sulfate) in disseminated malignant melanoma has been investigated in our oncology service in a phase-II study. Of 25 patients exposed to the drug, 23 were evaluable, and seven of these (30%) were considered objective responders. The observed response of malignant effusions is of particular interest. Side effects related to vindesine are similar to those of the other vinca alkaloids, although alopecia may be more pronounced with the doses used in this study.Keywords
This publication has 5 references indexed in Scilit:
- Results with methyl-CCNU and DTIC in metastatic melanomaCancer, 1977
- Phase I anti-cancer agents Vindesine (desacetyl vinblastine amide sulfate)Cancer Treatment Reviews, 1977
- COMBINATION CHEMOTHERAPY FOR DISSEMINATED MALIGNANT-MELANOMA WITH DTIC, VINCRISTINE, AND METHYL-CCNU1977
- Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanomaCancer, 1977
- Integration of chemotherapy into combined modality therapy of solid tumors: IV. Malignant melanomaCancer Treatment Reviews, 1974